Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Decreases By 62.8%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 190,658 shares, a decline of 62.8% from the March 31st total of 512,684 shares. Approximately 1.2% of the company’s shares are short sold. Based on an average daily volume of 199,535 shares, the days-to-cover ratio is currently 1.0 days.

Marker Therapeutics Stock Up 3.6%

NASDAQ MRKR opened at $1.45 on Tuesday. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.07. The company has a market capitalization of $24.17 million, a PE ratio of -1.71 and a beta of 1.47. The firm’s 50 day moving average is $1.45 and its 200-day moving average is $1.40.

Marker Therapeutics (NASDAQ:MRKR) last issued its earnings results on Wednesday, March 18th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.17. The business had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.68 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%. As a group, sell-side analysts expect that Marker Therapeutics will post -1.18 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Wall Street Zen raised shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Friday, March 27th. Finally, Zacks Research lowered shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On Marker Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in shares of Marker Therapeutics during the fourth quarter worth approximately $60,000. LPL Financial LLC boosted its position in shares of Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after acquiring an additional 24,500 shares during the period. Osaic Holdings Inc. grew its stake in shares of Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after acquiring an additional 13,340 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of Marker Therapeutics in the fourth quarter valued at about $222,000. Finally, Geode Capital Management LLC grew its stake in shares of Marker Therapeutics by 35.3% in the fourth quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after acquiring an additional 34,028 shares in the last quarter. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.